论文部分内容阅读
异名肽链内切酶、胰肽酶(Pancreatopeptidase)E、Elaszyme 来源从干燥胰粉得到的一种蛋白酶,特异性较宽,分子量约25,000。药效分类抗动脉粥样硬化药开发单位 (日)Eisai 上市厂商同上,1981年9月首次报道 J Jap Pharmacists Assn (Aug 1975) 药理 1.抑制动脉壁上脂肪和钙的沉积:大鼠实验证明本品对正常动脉弹性纤维的走向和排列完全没有影响,但在发生动脉硬化的大鼠则能选择性地作用于病变部位的动脉,能抑制和除去动脉壁变性弹性蛋白上
Synonymous Endopeptidase, Pancreatopeptidase E, Elaszyme Source A protease derived from dried pancreas powder, with a wide specificity and a molecular weight of about 25,000. Pharmacodynamic Category Anti-atherosclerotic drug development unit (day) Listed on the Eisai Maker, first reported in September 1981 J Jap Pharmacists Assn (Aug 1975) Pharmacology 1. Inhibition of deposition of fat and calcium on the arterial wall: Rat experimental evidence This product has no effect on the normal arterial elastic fibers and alignment, but in the occurrence of atherosclerosis rats can selectively act on the lesions of the artery, can inhibit and remove the arterial wall of the denatured elastin